.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
AstraZeneca
Cerilliant
Cantor Fitzgerald
UBS
Novartis
Baxter
Argus Health
Colorcon

Generated: June 29, 2017

DrugPatentWatch Database Preview

TEFLARO Drug Profile

« Back to Dashboard

What is the patent landscape for Teflaro, and what generic Teflaro alternatives are available?

Teflaro is a drug marketed by Cerexa and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in thirty-two countries.

The generic ingredient in TEFLARO is ceftaroline fosamil. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ceftaroline fosamil profile page.

Summary for Tradename: TEFLARO

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list4
Clinical Trials: see list12
Patent Applications: see list10
Drug Prices:see details
DailyMed Link:TEFLARO at DailyMed

Pharmacology for Tradename: TEFLARO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo7,419,973► SubscribeY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo6,417,175► SubscribeYY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes8,247,400► SubscribeY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes9,629,861► SubscribeY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo6,906,055► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TEFLARO

Drugname Dosage Strength RLD Submissiondate
ceftaroline fosamilInjection400 mg/vial and 600 mg/vialTeflaro10/29/2014

International Patent Family for Tradename: TEFLARO

Country Document Number Estimated Expiration
Canada2774772► Subscribe
Canada2314564► Subscribe
European Patent Office2020416► Subscribe
South Korea20030022891► Subscribe
Costa Rica20120137► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TEFLARO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 00120823
2Finland► Subscribe
134Luxembourg► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ZINFORO)
C0008France► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL, SES ESTERS OU SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
C/GB13/004United Kingdom► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/12/785/001 20120823
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
McKesson
Colorcon
Deloitte
Queensland Health
Accenture
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot